Business
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
- Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing - Phase 2a PET imaging trial of PLN-74809 in IPF enrolling - Completed dosing of
About this update from Pliant Therapeutics, Inc.
[{"type":"text","content":"- Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing\n - Phase 2a PET imaging trial of PLN-74809 in IPF enrolling\n - Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers\n\n\nSOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2020 financial results.\n\n \n \n \n \n \n \n\n \n\"Reflecting back on the first three quarters of 2020, I'm proud of the progress we've made despite the challenges related to the COVID-19 pandemic,\" said Bernard Coulie, M.D., Ph.D., Chief Executive Officer and President of Pliant Therapeutics. \"We closed a successful IPO, took important steps in advancing our clinical programs across four indications, and further strengthened our leadership team. Looking ahead, with a strong cash position to advance our robust pipeline, we remain deeply committed to bringing novel treatments to people with fibrotic diseases.\"\nRecent Highlights\nEnrollment of Phase 2a 12-week trials of PLN-74809 in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) progressing. After resuming enrollment earlier in the year, Pliant has remained in close coordination with its global trial sites in order to facilitate enrollment in both Phase 2a trials. The Company also continues to open additional trial sites as COVID-19 related restrictions are eased. The hybrid approach to clinical trial participation utilizing home-health solutions to maximize patient safety is expected to aid in trial recruitment. Phase 2a PET imaging trial of PLN-74809 in IPF is enrolling. The Phase 2a PET trial will evaluate safety, tolerability, and target engagement of PLN-74809 in IPF patients. We expect to report preliminary data by the first half of 2021. Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers. PLN-74809 has completed dosing multiple ascending dose cohorts of 120mg and 160mg once daily in an extended dose escalation trial. The pharmacokinetic profile remains in line with previous cohorts, and PLN-74809 remains generally well tolerated with no drug related severe a...